TW201444595A - Insulin injection apparatus - Google Patents

Abstract

The present invention is related to an insulin injection apparatus having a body and an injection controller. The body is mounted inside a human body and having a container, an opening, an osmotic device and an injection device. The container is size changeable and is containing insulin therein. The opening is mounted on the body and mounts the injection controller and the injection device therein. The osmotic device is mounted on the body and is able to transfer the insulin into the human body. The injection controller changes the size of the body to enhance the insulin transferring speed into the human body.

Description

Insulin injection device

Modern people's diet is not balanced, often leading to the occurrence of many civilized diseases, diabetes is one of them.

In diabetic patients, insulin must be injected regularly and quantitatively to maintain normal living functions. However, patients usually have to bring their own syringes to inject insulin at a certain time. This not only causes the patient to carry many drugs at any time, but is also more likely to be injected in some cases, causing many inconveniences in the patient's life.

Although some electric syringes that can automatically inject insulin are available today, although the problem of troubles caused by injection can be avoided, the patient must always carry the relevant equipment, causing another inconvenience.

In order to solve the technical problems that the injection insulin device is inconvenient and troublesome to the patient, the invention is an implantable syringe which can be implanted in the human body and can be injected with a relatively large amount of insulin before being gradually released. It is used by the human body. Therefore, it is necessary to avoid the trouble of frequent injection for a certain period of time, and it is more difficult to carry the problem because it can be implanted in the body.

The invention provides an insulin injection device, which comprises a body and a body An injection control assembly, the system can be implanted into a human body, wherein: the body comprises a receiving capsule, a stoma, a permeating member, and an injecting block, wherein the receiving capsule is a deformable and accommodating capsule. The utility model is made of a biocompatible material and has an accommodating space therein, and the accommodating space is filled with an insulin; the stoma is protruded from the surface of the accommodating sac, and the inside of the accommodating capsule and the injection control component are accommodated therein. The osmotic member is an osmotic liquid or a film which can be permeable to the released liquid under a specific pressure; the injection block is embedded in the stoma, and the partial surface thereof and the accommodating space of the accommodating sac and the air outside the human body respectively Correspondingly, it is a soft rubber block; the injection control component changes the size of the accommodating capsule to change the internal pressure of the accommodating space, so that the insulin capacity in the accommodating capsule changes.

Further, the body of the implanted osmotic insulin syringe comprises a pull plate fixedly connected to the receiving capsule, and is disposed on an opposite inner side surface of the stoma of the receiving capsule; the injection control assembly comprises a central processing And a driving film group, a battery, a pressure sensing unit, a blood glucose sensing unit and an input unit electrically connected to the central processing unit; the driving module comprises a driving unit and is fixed to the driving unit Connecting a screw and a pull rod, the driving unit is fixedly disposed in the stoma, and is controlled by the central processor to rotate the screw, the screw is correspondingly engaged with the pull rod, and the pull rod is fixedly disposed on the pull rod a driving unit driving the screw to move the rod relative to the screw to change a size and an internal pressure of the accommodating space of the accommodating bag; the pressure sensing unit senses an internal pressure of the accommodating space, and senses The measurement result is output to the central processing unit; the blood glucose sensing unit senses a blood sugar level of the human body, and outputs the sensed blood sugar level value to the central processor; the input unit is Human input via the injection control assembly The central processor drives the driving module to perform a corresponding change in the size and internal pressure of the container according to the sensed blood glucose level and the internal pressure sensing result.

Wherein, the injection block may be provided with an antibacterial surface layer on a surface in contact with the air.

The injection control component includes an illumination unit and an audio output unit electrically connected to the central processing unit, and the illumination unit and the sound output unit are respectively driven by the central processor and are based on internal pressure and insulin inventory. Produces light and sound output.

Further, the implanted osmotic insulin syringe comprises a spacer sleeve, which is a sealing kit with flexing or telescoping, sleeved outside the driving module and closely connected with the inner surface of the receiving capsule.

The central processing unit inputs a plurality of neural network calculations according to the plurality of blood glucose sensing results, gender, and weight, and generates a control command for controlling the driving module to change the size and internal pressure of the receiving capsule.

Wherein, the central processing unit executes a filling mode program to perform an insulin filling control operation, and the flow steps are as follows: starting an insulin filling mold; reading a pressure sensor signal and calculating a pressure value: the central processor reads the pressure sensing The internal pressure of the accommodating space sensed by the unit, and the internal pressure value is calculated; the central processor determines whether the pressure value of the accommodating space is greater than a critical range, and the pressure of the central processing unit in the accommodating space is greater than a setting The critical range of driving, the driving unit adjusts the relative position of the screw and the rod to enlarge the accommodating space, and the pressure of the accommodating space is changed. The insulin filling syringe injects insulin into the accommodating capsule; and the central processor determines that the pressure value of the accommodating space is lower than the critical range, stops driving the driving unit, and drives the illuminating unit or the sound output unit to generate a warning light source or sound.

Wherein, the central processing unit performs an automatic injection process, which comprises the steps of: inputting, by the input unit or wireless transmission mode, a gender and a weight, and an insulin injection quantity influence parameter to the central processor; the blood glucose sensing unit is based on Reading the blood glucose value of the user at a set time; the central processor reads the blood glucose value, and determines whether a set number of blood glucose values are obtained within a set time range; the central processor performs a neural network-like operation The blood glucose sensing value of the last several times affects the parameter as an input parameter of the input layer, and generates an injection parameter command after calculation; and the central processor generates an injection parameter command to control the driving unit according to the pressure of the accommodating space. One of the rotational speed control commands, the control command enables the drive unit to infiltrate the insulin dose required by the user to the human body.

Further, the automatic injection program includes the steps of: calculating a residual insulin inventory: the central processor calculates the insulin stock stored in the accommodating capsule according to the positional relationship between the driving unit and the pull rod, and the sensing result of the pressure sensing unit; The central processor drives the sound output unit or the light unit to generate an alert sound and light output after the calculated insulin stock is lower than a safe stock.

As can be seen from the foregoing description, the present invention has the following advantages:

1. It can be implanted into the human body and automatically infiltrate insulin to the human body according to the needs of the patient's body, and continuously monitor the blood sugar state of the human body after infiltration.

2. When the insulin stock is insufficient, a sound or light warning is generated, so that the user can inject a relatively large amount of stock (for example, one day) into the human body with a syringe. The patient can inject insulin once a day or several days, and go out. It is no longer necessary to carry syringes, drugs or automatic injection devices to greatly improve the quality of life of patients.

10‧‧‧ Ontology

10A‧‧‧ accommodating space

12‧‧‧Capsule

13‧‧‧ostomy

14‧‧‧Permeable parts

15‧‧‧Injection block

16‧‧‧ pull board

20‧‧‧Injection control components

21‧‧‧Central Processing Unit

22‧‧‧Battery

23‧‧‧Drive Module

231‧‧‧ drive unit

232‧‧‧ screw

234‧‧‧ lever

24‧‧‧Lighting unit

25‧‧‧Sound output unit

26‧‧‧ Pressure sensing unit

27‧‧‧ Blood glucose sensing unit

28‧‧‧Input unit

40‧‧‧Isolation Kit

50‧‧‧Syringe

The first figure is a perspective view of a preferred embodiment of the invention.

The second figure is a side elevational cross-sectional view of a preferred embodiment of the invention.

The third figure is a front view of a preferred embodiment of the present invention.

The fourth figure is a schematic view of the use of the preferred embodiment of the present invention.

Figure 5 is a schematic illustration of the use of a preferred embodiment of the invention.

Figure 6 is a block diagram of a circuit in accordance with a preferred embodiment of the present invention.

Figure 7 is a schematic view of the process of filling insulin according to a preferred embodiment of the present invention.

Figure 8 is a schematic view showing the flow of insulin injection in accordance with a preferred embodiment of the present invention.

Figure 9 is a schematic diagram of a neural computing network in accordance with a preferred embodiment of the present invention.

Please refer to the first to third figures for the insulin injection device of the present invention. The preferred embodiment comprises a body 10 and an injection control assembly 20. The body 10 includes a receiving capsule 12, a stoma 13, a permeable member 14, an injection block 15, and a pull plate 16. In use, the body 10 can be implanted in a human body near the surface of the skin.

The accommodating capsule 12 is a deformable accommodating capsule which is made of a biocompatible material so as not to cause repulsion in a human body. The accommodating capsule 12 of the present embodiment has a dish shape and an inner portion. Contains an accommodation space 10A. The stoma 13 protrudes from the surface of the accommodating bag, and the injection block 15 and the injection control assembly 20 are accommodated therein. The permeating member 14 is a permeating block or film which can be penetrated and released under a specific pressure by an insulin liquid, and the material thereof can be, for example, a ceramic having a specific pore or the like.

The injection block 15 is embedded in the stoma 13 and has a partial surface corresponding to the accommodating space 10A of the accommodating capsule 12 and the external air outside the human body, and is a soft rubber block such as silicone rubber. Further, the injection block 15 may be provided with an antibacterial surface layer on the surface in contact with the air to reduce the risk of bacterial infection in the air, and the antibacterial surface layer may be a coating or film of nano photocatalytic effect.

The pull plate 16 is fixedly connected to the receiving pocket 12 and is disposed on the opposite inner side surface of the stoma 13 of the receiving capsule 12.

The injection control unit 20 includes a central processing unit 21 and a driving film group 23 electrically connected to the central processing unit 21, a battery 22, a light emitting unit 24, a sound output unit 25, and a pressure sensing unit 26. a blood glucose sensing unit 27 and an input unit 28.

The driving module 23 includes a driving unit 231, a screw 232 fixedly connected to the driving unit 231, and a pull rod 234. The driving unit 231 is fixed. It is disposed in the stoma 13 and is controlled by the central processing unit 21 to rotate the screw 232. The screw 232 is sleeved on the pull rod 234, and the pull rod 234 is fixedly disposed on the pull plate 16. After the driving unit 231 drives the screw 232, the pull rod 234 is moved relative to the screw 232, thereby driving the pulling plate 16 to change the size and internal pressure of the receiving space 10A of the receiving bag 12.

The battery 22 provides the power required to operate the electronic components within the injection control assembly 20. The light-emitting unit 24 and the sound output unit 25 are respectively driven by the central processing unit 21 to generate light and sound output. The pressure sensing unit 26 senses the internal pressure of the accommodating space 10A and outputs the sensing result to the central processing unit 21. The blood glucose sensing unit 27 senses a blood sugar level of a human body, and outputs the sensed blood sugar level to the central processing unit 21. The input unit 28 is a human input interface of the injection control assembly 20.

The central processing unit 21 drives the light-emitting unit 24, the sound output unit 25, and the driving module 23 to perform corresponding control actions according to the sensed blood glucose level and the internal pressure sensing result. When the blood glucose level and the internal pressure value exceed a critical setting, the illumination unit 24 and the sound output unit 25 generate light and sound output, thereby alerting the user to the blood glucose or the imbalance in the body; and the driving module 23 is simultaneously driven. The internal pressure is changed to receive the injection of insulin or the insulin is output to the user through the permeate 14.

In order to prevent the operation of the driving module 23 from contaminating the insulin stored in the accommodating space 10A, the isolation module 40 is not sleeved outside the driving module 23, and the isolation package 40 is a sealing package with flexing or telescopic locking. The sleeve is disposed outside the driving module 23 and is in close contact with the inner surface of the receiving capsule 12 .

Referring to the fourth and fifth figures, when the pressure of the accommodating space 10A is insufficient to generate an audible or visual warning, the user can insert a syringe 50 into the injection block 15 to inject an insulin into the accommodating space 10A. (Fig. 4(a)), the central processing unit 21 continuously senses the internal pressure to drive the driving module 23, so that insulin can be smoothly injected and filled in the accommodating space ((Fig. 4(b)) ). After the filling process is completed, the user can manipulate the input unit 28 to convert the embodiment into an automatic insulin supplementing program, so that the central processing unit 21 slightly increases the accommodating space 10A according to the blood glucose concentration and the internal pressure of the sensed human body. The pressure causes insulin to permeate into the human body from the accommodation space 10A ((Fig. 4(c))). When the pressure of the accommodating space 10A cannot be changed by adjusting the driving module 23, and it is necessary that the insulin has been filled with 罄 ((Fig. 4(d))), the filling procedure is repeated.

Referring to the seventh, eighth, and ninth diagrams, the central processing unit 21 can respectively perform a filling mode program and an automatic injection program to respectively perform the aforementioned insulin filling and injecting body control actions, wherein the filling mode program The process steps are as follows:

S1. Start the insulin filling mold.

S2. Reading the pressure sensor signal and calculating the pressure value: the central processing unit 21 reads the internal pressure of the accommodating space 10A sensed by the pressure sensing unit 26, and calculates the internal pressure value.

S3. Injecting insulin into the insulin field syringe: The user inserts insulin into the injection block 15 with the syringe 50 to start injecting insulin.

S4. Whether the pressure value is greater than R: The central processing unit 21 determines whether the pressure value of the accommodating space is greater than a critical range R. If it is greater than the threshold value R, step s5 is performed, and if not, step s4 is performed.

S5. driving the servo motor rotating screw: the pressure of the central processing unit 21 in the accommodating space 10A is greater than a set critical range R, driving the driving unit 231 to adjust the relative position of the screw 232 and the pull rod 234, so as to make the accommodating space 10A is enlarged, and the pressure of the accommodating space 10A is changed to assist the filling of the insulin syringe to inject insulin into the accommodating capsule 12.

S6. Whether the pressure value is less than R: the central processing unit 21 continues to determine whether the pressure of the accommodating space 10A is within the critical range R, and if it is lower than the critical range R, stops driving the servo motor of the driving unit 231, and The illumination unit 24 or the sound output unit 25 is driven to generate an alert light source or sound, thereby indicating that the saturation fill completes the filling procedure.

In the automatic injection program, it contains the following steps:

P1. Initiate insulin injection mode.

P2. Input gender and personal weight: The input unit 28 or wireless transmission mode inputs gender, body weight, and the like, one injection amount of insulin influence parameter to the central processing unit 21.

P3. Reading the blood glucose sensing signal according to the time interval: the blood glucose sensing unit 27 reads the blood sugar level of the user according to a set time.

P4. Reading the blood glucose data and determining whether the number of detections exceeds a set number of times: the central processing unit 21 reads the blood glucose level, and determines whether a set number of blood glucose values are obtained within a set time range; for example, the central processing The device 21 determines whether or not the updated three-time blood glucose value is obtained every three hours.

P5. performing a type of neural network operation with the injection quantity influence parameter and the blood glucose data and outputting an injection parameter command: the central processing unit 21 performs a neural network-like operation, and takes the blood glucose sensing value of the last three times to influence the injection quantity influence parameter ( Weight, gender, etc. as input parameters of the input layer, calculated to produce one Injection parameter instructions.

P6. Calculating the control command of the driving module, adjusting the insulin injection amount: the central processing unit 21 generates an injection parameter command, and the pressure of the accommodating space generates a control command for controlling the rotation speed of the driving unit 231, the control command makes the driving Unit 231 can infiltrate the insulin dose required by the user to the human body.

P7. Calculating the residual insulin stock: The central processing unit 21 calculates the insulin stock stored in the accommodating capsule 12 according to the positional relationship between the driving unit 231 and the pull rod 234 and the sensing result of the pressure sensing unit 26.

P8. Insufficient inventory to generate a voice alert: the central processor 21 drives the sound output unit 25 or the light emitting unit 24 to generate an alert sound and light output after the calculated insulin stock is lower than a safe stock.

As can be seen from the foregoing description, the present invention has the following advantages:

1. It can be implanted into the human body and automatically infiltrate insulin to the human body according to the needs of the patient's body, and continuously monitor the blood sugar state of the human body after infiltration.

2. When the insulin stock is insufficient, a sound or light warning is generated, so that the user can inject a relatively large amount of stock (for example, one day) into the human body with a syringe. The patient can inject insulin once a day or several days, and go out. It is no longer necessary to carry syringes, drugs or automatic injection devices to greatly improve the quality of life of patients.

10‧‧‧ Ontology

14‧‧‧Permeable parts

16‧‧‧ pull board

Claims (9)

An insulin injection device comprising a body and an injection control assembly, wherein the system can be implanted into a human body, wherein: the body comprises a receiving capsule, a stoma, a permeating member, and an injecting block, the receiving capsule The invention has a deformable and accommodating capsule which is made of a biocompatible material and has an accommodating space therein, the accommodating space is filled with an insulin; the stoma is protruded from the surface of the accommodating capsule, and the inside thereof Accommodating the injection block and the injection control assembly, the permeate member is an infiltration block or film that can be penetrated and released under a specific pressure; the injection block is embedded in the stoma, and the partial surface thereof is respectively associated with the volume The accommodating space corresponding to the external air of one person is a soft rubber block; and the injection control component changes the size of the accommodating bag to change the internal pressure of the accommodating space to make the accommodating space The insulin capacity changes. The implantable osmotic insulin syringe according to claim 1, wherein the body comprises a pull plate fixedly connected to the accommodating capsule, and is disposed on an opposite inner side surface of the stoma of the accommodating capsule; The injection control unit includes a central processing unit and a driving film group electrically connected to the central processing unit, a battery, a pressure sensing unit, a blood glucose sensing unit and an input unit, wherein: the driving module The utility model comprises a driving unit, a screw fixedly connected to the driving unit and a pull rod, wherein the driving unit is fixedly disposed in the stoma, and is controlled by the central processor to rotate the screw, wherein the screw is correspondingly engaged with the screw a pull rod, the pull rod is fixedly disposed on the pull plate, and the driving unit drives the screw to move the pull rod relative to the screw to change the receiving pocket The size of the accommodating space and the internal pressure; the pressure sensing unit senses the internal pressure of the accommodating space, and outputs the sensing result to the central processor; the blood glucose sensing unit senses a blood sugar level of the human body, and senses The blood glucose value is output to the central processing unit; the input unit is a human-machine input interface of the injection control component; and the central processor drives the driving module to perform a corresponding change according to the sensed blood glucose value and the internal pressure sensing result. Capacitor size and internal pressure. The implantable osmotic insulin syringe of claim 1, wherein the injection block can be provided with an antimicrobial surface layer on a surface in contact with the air. The implantable osmotic insulin injector according to claim 2, wherein the injection control component comprises an illumination unit and an audio output unit electrically connected to the central processing unit, wherein the illumination unit and the sound output unit respectively It receives the driving of the central processing unit and generates light and sound output according to the internal pressure and the stock of insulin. The implantable osmotic insulin syringe of claim 2, wherein the isolation kit is a sealing kit having a flexing or telescoping sleeve, and is disposed outside the driving module. It is in close contact with the inner surface of the container. The implantable osmotic insulin syringe according to claim 5, wherein the central processing unit inputs the blood glucose sensing result, the sex, and the weight into a type of neural network calculation to generate a control module. The control command changes the size and internal pressure of the container. The implantable osmotic insulin injector according to claim 6, wherein the central processor executes a filling mode program to perform an insulin filling control operation, and the flow steps are as follows: starting an insulin filling mold; reading the pressure sensor The signal and the calculated pressure value: the central processor reads the internal pressure of the accommodating space sensed by the pressure sensing unit, and calculates the internal pressure value; the central processor determines whether the pressure value of the accommodating space is greater than one a critical range, the pressure of the central processing unit in the accommodating space is greater than a set critical range, driving the driving unit to adjust the relative position of the screw and the rod to enlarge the accommodating space, and the pressure of the accommodating space is changed. Assisting the filling of the insulin syringe to inject insulin into the accommodating capsule; and the central processor determines that the pressure value of the accommodating space is lower than the critical range, stops driving the driving unit, and drives the illuminating unit or the sound output unit to generate the warning light source Or sound. The implantable osmotic insulin syringe according to claim 7, wherein the central processor performs an automatic injection procedure comprising the steps of: inputting one of sex and body weight with the input unit or wireless transmission mode The injection quantity affects the parameter to the central processor; the blood glucose sensing unit reads the blood glucose value of the user according to a set time; the central processor reads the blood sugar level, and determines whether a set number of times is obtained within a set time range Blood glucose value; the central processor operates on a neural network, taking the most recent blood glucose Sensing the value of the injection quantity affecting the parameter as an input parameter of the input layer, and generating an injection parameter command after calculation; and the central processor generates an injection parameter command, and the pressure of the accommodating space generates a control command for controlling the rotation speed of the driving unit. The control command enables the drive unit to infiltrate the insulin dose required by the user to the human body. The implantable osmotic insulin syringe according to claim 8, wherein the automatic injection procedure comprises the steps of: calculating a residual insulin stock: the central processing unit according to the positional relationship between the driving unit and the rod, the pressure sensing unit The sensing result is used to calculate the insulin stock stored in the accommodating capsule; the central processor drives the sound output unit or the illuminating unit to generate an alert sound and light output after the calculated insulin stock is lower than a safe stock.